Evidence map›Paper›PMID 40799424›Full record

ArticleTranslational lung cancer research2025

Radiomics-clinical integration guides prophylactic cranial irradiation decisions in limited-stage small cell lung cancer: a brain metastasis risk stratification model.

Yuntao Zhou, Li Xiao, Siyi Yang, Chengwen Yang, Jifeng Sun, Jiehan Wu, Zhiyong Cui, Lujun Zhao, Yunchuan Sun, Ningbo Liu

Abstract read
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuntao Zhou *Department of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China.
Li Xiao *Department of Radiation Oncology, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Cangzhou, China.
Siyi Yang *Department of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China.
Chengwen YangDepartment of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China.
Jifeng SunDepartment of Radiotherapy, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
Jiehan WuDepartment of Medical Technology, Langfang Health Vocational College, Langfang, China.
Zhiyong CuiDepartment of Radiotherapy, Hetian District People's Hospital, Hetian, China.
Lujun ZhaoDepartment of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China.
Yunchuan SunDepartment of Radiation Oncology, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Cangzhou, China.
Ningbo LiuDepartment of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Limited-stage small-cell lung cancer (LS-SCLC) is highly aggressive and prone to brain metastasis (BM). Early identification of BM risk is crucial for devising personalized prophylactic cranial irradiation (PCI) strategies. This study aimed to develop a multimodal model integrating radiomic and clinical features to stratify BM risk in LS-SCLC patients and guide personalized PCI strategies. Methods: This study analyzed 141 LS-SCLC patients (2013-2021) using computed tomography (CT) images and clinical records. Patients were randomly divided into training (n=98), internal validation (n=43), and external validation cohorts (n=24). Radiomic features were extracted and optimized using the minimum redundancy maximum relevance (mRMR) algorithm to form a radiomic score (RadScore). Clinical predictors were identified via univariate logistic regression (LR). Four machine learning models-LR, support vector machine, random forest, and eXtreme Gradient Boosting-were used to develop predictive models. Model performance was evaluated by the area under the receiver operating characteristic curve (AUC). Results: A total of 141 patients (mean age, 59.03 years; 109 men and 32 women) were evaluated. A total of 1,037 radiomic features were extracted from the simulated positioning CT images, with 10 optimal features selected to form the RadScore. By incorporating dynamic changes in platelet count, hemoglobin levels, and leukocyte indices before and after radiotherapy, along with the baseline lymphocyte-to-monocyte ratio (LMR), the LR combined model demonstrated superior predictive capability. The LR combined model showed superior performance with AUCs of 0.831 (training), 0.831 (internal validation), and 0.863 (external validation). Risk stratification indicated that PCI reduced BM risk in high-risk patients [hazard ratio (HR) =0.270, P<0.001] but not in low-risk patients (HR =0.225, P=0.13). Conclusions: The LR combined radiomic-clinical model demonstrated superior predictive performance. PCI significantly reduced the risk of BM in high-risk patients, whereas no statistically significant benefit was observed in low-risk patients.

Indexed as

brain metastasis (BM)Limited-stage small cell lung cancer (LS-SCLC)machine learningradiomicradiotherapy

Identifiers

PMID40799424
PMCPMC12337071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.